Pfizer (NYSE:PFE) Releases FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.800-3.000 for the period, compared to the consensus earnings per share estimate of 2.970. The company issued revenue guidance of $60.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.7 billion.

Pfizer Trading Up 0.2%

Pfizer stock traded up $0.05 during trading on Thursday, hitting $25.86. The company had a trading volume of 13,573,440 shares, compared to its average volume of 42,234,152. Pfizer has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s 50 day simple moving average is $25.01 and its 200-day simple moving average is $26.16. The stock has a market cap of $147.40 billion, a price-to-earnings ratio of 34.02 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Guggenheim decreased their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.50.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer exceeded second-quarter earnings and revenue expectations, supported by strong demand for the blood thinner Eliquis and growth from newer and acquired products. The company raised the low end of its 2026 revenue outlook, with guidance reaching as high as $62.5 billion. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Management identified continued non-COVID growth, deeper cost reductions and pipeline catalysts as key recovery drivers. Pfizer is targeting an additional $2.5 billion in savings, which could support margins and earnings over time. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: A positive Phase 3 readout for Litfulo in vitiligo adds a potential new indication for Pfizer’s commercial portfolio and supports the company’s effort to diversify beyond COVID products. Pfizer Reports Positive Phase 3 LITFULO Data In Vitiligo
• Neutral Sentiment: Investor attention remains focused on Pfizer’s obesity-drug program. Upcoming data could become a significant catalyst, but recent setbacks and uncertainty over the candidate’s competitiveness temper enthusiasm. Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout Looms
• Negative Sentiment: COVID-related revenue remains under severe pressure, including a reported 95% plunge in sales of Pfizer’s COVID antiviral. Patent expirations, a reported quarterly net loss and noncash impairments also keep longer-term growth and pipeline execution concerns in focus. Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in shares of Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.